Schlemmer U, Frølich W et al. Phytate in foods and significance for humans: food sources, intake, processing, bioavailability, protective role and analysis. Mol Nutr Food Res. 2009 Sep;53 Suppl 2:S330-75

Silva EO, Bracarense AP. Phytic acid: From antinutritional to multiple protection factor of organic systems. J Food Sci. 2016 Jun;81(6):R1357-62

Scheers N, Rossander-Hulthen L et al. Increased iron bioavailability from lactic-fermented vegetables is likely an effect of promoting the formation of ferric iron (Fe(3+)). Eur J Nutr. 2016 Feb;55(1):373-82

Beck KL, Conlon CA et al. Dietary determinants of and possible solutions to iron deficiency for young women living in industrialized countries: a review. Nutrients. 2014 Sep 19;6(9):3747-76. doi: 10.3390/nu6093747

Armah SM, Boy E, Chen D et al. Regular consumption of a high-phytate diet reduces the inhibitory effect of phytate on nonheme-iron absorption in women with suboptimal iron stores. J Nutr. 2015 Aug;145(8):1735-9

Williams C, Ronco C, Kotanko P. Whole grains in the renal diet--is it time to reevaluate their role? Blood Purif. 2013;36(3-4):210-4

Hypothesis: Phytate is an important unrecognised nutrient and potential intravenous drug for preventing vascular calcification.

Protective effect of myo-inositol hexaphosphate (phytate) on abdominal aortic calcification in patients with chronic kidney disease.

Bacić I, Druzijanić N et al. Efficacy of IP6 + inositol in the treatment of breast cancer patients receiving chemotherapy: prospective, randomized, pilot clinical study. J Exp Clin Cancer Res. 2010 Feb 12;29:12

Druzijanic N, Jurici J, Perko K et al. IP6 + inositol as adjuvant to chemotherapy of colon cancer: our clinical experience. Anticancer Res. 2004; 24:3474

Juricic J, Druzijanic N, Perko Z et al. IP6 + inositol in treatment of ductal invasive breastcancer carcinoma: our clinical experience. Anticancer Res. 2004; 24:3475

Vucenik I, Shamsuddin AM. Protection against cancer by dietary IP6 and inositol. Nutr Cancer. 2006;55(2):109-25.

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/ucm171057.htm

Wilson MS, Bulley SJ et al. A novel method for the purification of inositol phosphates from biological samples reveals that no phytate is present in human plasma or urine. Open Biol. 2015 Mar;5(3):150014

Sandstead HH, Freeland-Graves JH. Dietary phytate, zinc and hidden zinc deficiency. J Trace Elem Med Biol. 2014 Oct;28(4):414-7

Williams C, Ronco C, Kotanko P. Whole grains in the renal diet--is it time to reevaluate their role? Blood Purif. 2013;36(3-4):210-4

Grases F, Saez-Torres C, Rodriguez A et al. Urinary phytate (Myo-inositol hexaphosphate) in healthy school children and risk of nephrolithiasis. J Ren Nutr. 2014 Jul;24(4):219-23

Grases F, March JG, Prieto RM et al. Urinary phytate in calcium oxalate stone formers and healthy people--dietary effects on phytate excretion. Scand J Urol Nephrol. 2000 Jun;34(3):162-4

Grases F1, Rodriguez A2 et al. Efficacy of mixtures of magnesium, citrate and phytate as calcium oxalate crystallization inhibitors in urine. J Urol. 2015 Sep;194(3):812-9

Conte A1, Pizá P, García-Raja A. Urinary lithogen risk test: usefulness in the evaluation of renal lithiasis treatment using crystallization inhibitors (citrate and phytate). Arch Esp Urol. 1999 Jan-Feb;52(1):94-9

Lopez-Gonzalez AA, Grases F et al. Phytate levels and bone parameters: a retrospective pilot clinical trial. Front Biosci (Elite Ed). 2010 Jun 1;2:1093-8

López-González AA, Grases F, Monroy N et al. Protective effect of myo-inositol hexaphosphate (phytate) on bone mass loss in postmenopausal women. Eur J Nutr. 2013 Mar;52(2):717-26